Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 July 2023 | Story André Damons | Photo Supplied
Dr Mirriam Moleko
Dr Mirriam Moleko, a lecturer in the Department of Mathematics, Natural Sciences, and Technology Education in the UFS Faculty of Education, participated in the National Research Foundation’s Black Academics Advancement Programme fellowship and got the opportunity to visit universities and schools in the USA for three weeks.

After completing the National Research Foundation’s Black Academics Advancement Programme (BAAP) fellowship, a lecturer from the University of the Free State (UFS) now wants to train more teachers on issues of access and inclusivity in different mathematics settings. She also wants to establish a centre for access and inclusivity to promote quality teaching that caters to a diverse learner population.

Dr Mirriam Moleko, a lecturer in the UFS’s Department of Mathematics, Natural Sciences, and Technology Education in the Faculty of Education, participated in the BAAP fellowship, an initiative of the National Research Foundation (NRF) and the FirstRand Foundation (FRF), from 2021 to 2022. She also got the opportunity to visit universities and schools in the USA for three weeks.

Supporting emerging academics

Dr Moleko says the BAAP is a prestigious NRF programme which supports well-structured research projects with achievable aims, sound methodologies, and demonstrated prudent use of funds. The programme supports emerging academics to ensure that they develop strong research skills, collaborate with prolific scholars in their fields, visit other universities abroad, give public lectures, and attend international conferences to establish an international footprint.

“The programme allows the candidates awarded the grant to focus on research for two years” she says. “I managed to run my teacher community research project successfully during this period. My goal as an academic and a researcher is to produce work that teachers can relate to and be able to apply in their profession. I have always aspired to empower teachers to be knowledgeable and resourceful”.

“Furthermore, my goal is to strive to partake in critical conversations that are taking place within the mathematics education field, and to contribute my skills and knowledge in addressing the existing challenges, thus being part of the solution. I believe the skills that I have gained on how to conduct quality research will assist me in achieving my goals,” she added.

Benefit from funding

During the period of her fellowship she learned about forming partnerships and collaborating with other scholars in her field, which she believes is an important skill to possess as a developing scholar.

Dr Moleko says the programme played a pivotal role in the attainment of numerous significant accomplishments in her professional career thus far. She also benefitted in terms of funding, which helped her undertake autonomous research and advanced training in her area of expertise, as well as facilitated engagement in collaborative research ventures with esteemed professionals and researchers, both domestically and abroad.

“The research leave that I got enabled me to successfully conceptualise, strategise, and implement a research endeavour that yielded a more profound comprehension of the research gap that I had identified within the teacher community, thus culminating in multiple publications in esteemed periodicals.

“The NRF-BAAP funding also enabled me to undertake training, thereby refining my skill set and augmenting my comprehension of intricate principles. The experience proved to be a crucial factor in my vocational growth and bolstered my aptitude for scholarly inquiry. It also afforded me the chance to engage in mentoring endeavours for fledgling researchers.”

Transformation of the Professoriate Mentoring Programme

Dr Moleko, who is part of the UFS Transformation of the Professoriate Mentoring Programme, says this programme is an excellent initiative which is aimed at preparing young academics for future promotions and offering them skills to be competitive. The programme’s goals include building strong academics who will follow in the footsteps of the university’s current leaders.

She says the programme is critical in supporting young academics by connecting them with seasoned mentors and scholars from various fields of study. It is essential for young academics in terms of maximising their learning, expanding their network, and gaining opportunities to help facilitate their growth.

“I see the programme as a catalyst for change necessary for the university to realise the desired results,” Dr Moleko says.

During her visit to the USA she spent two weeks at Boston College and the University of Rhode Island, and also visited the Center for Applied and Specialised Technology, the Paul V. Sherlock Center on Disabilities (Sherlock Center), and the TechACCESS Center.

“The purpose of my visit was to establish networks and collaborate with prolific scholars outside South Africa on research engagements. Furthermore, the visit was intended for me to meet with my international mentors in person regarding research engagements.

“During my research visit, Prof Elizabeth Dalton from Rhode Island University and a UDL specialist, and I focused on several academic conversations and demonstrations of Universal Design for Learning (UDL) strategies and approaches, as well as the sharing of many online resources available to support the implementation of UDL in inclusive settings.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept